Fusion protein comprising CCL3 variant and use thereof

Patent metadata

Field	Value
Publication number	US-11046742-B2
Application number	US-201716097572-A
Country	US
Kind code	B2
Filing date	Apr 19, 2017
Priority date	Apr 29, 2016
Publication date	Jun 29, 2021
Grant date	Jun 29, 2021

Abstract

Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3α or CCL3β is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3α or CCL3β in the CCL3 variant.

First claim

What is claimed is:

1. A fusion protein comprising a variant of CC type ligand 3β (CCL3β) and an immunoglobulin Fc region:
wherein the CCL3β variant comprises the sequence of SEQ ID NO: 4
wherein the CCL3β variant is linked to an immunoglobulin Fc region through a linker comprising the sequence of SEQ ID NO: 5, and
wherein the immunoglobulin Fc region comprises the sequence of SEQ ID NO: 14.

2. A nucleic acid encoding the fusion protein according to claim 1 .

3. A vector comprising the nucleic acid according to claim 2 .

4. A cell transformed by the vector according to claim 3 .

5. A method of preparing a fusion protein according to claim 1 , said method comprising:
(a) culturing a cell transformed by a vector comprising a nucleic acid encoding said fusion protein; and
(b) collecting the fusion protein from the cultured cell.

6. A method for treating a cancer comprising administering a pharmaceutical composition comprising the fusion protein according to claim 1 .

7. The method according to claim 6 , wherein the composition is administered in combination with radiation treatment.

8. The method according to claim 6 , wherein the composition is administered to assist radiation treatment.

Assignees

• Yuhan Corp

Inventors

• Nam Su Youn
• Kim Jong Gyun
• Choi Byung Hyun
• Lee June Hyung
• Park Ju Young
• Lee Jun Kyung
• Lee Na Rae
• Kim Ki Hong
• Kim Seul Gi
• Oh Se Woong
• Shin Seung Yub
• Kang Ho Woong
• Ahn Su Jin
• Chung Soo Yong

Classifications

• C07K14/522 Primary

  Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC · CPC title

• A61K38/195

  Chemokines, e.g. RANTES · CPC title

• A61K47/642

  the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate · CPC title

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• C12N15/11

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title